Europe — EMA
Nebilet (Nebivolol)
GNH USA supplies Nebilet (Nebivolol), a beta blocker for hypertension and heart failure, approved for adult patients. Request a quote for global supply.
Request sourcing
What is Nebivolol?
Nebivolol, the active ingredient in Nebilet, is a beta blocker presented as a tablet for oral use. It treats hypertension and heart failure in adult patients, helping to lower blood pressure and improve cardiac function. GNH USA supplies Nebilet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.
What is Nebivolol used for?
Nebivolol is indicated for conditions within the cardiovascular disease spectrum, primarily affecting blood pressure regulation and cardiac performance. Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of cardiovascular events. Heart failure: enhances left‑ventricular ejection fraction and decreases hospitalisation rates in patients with chronic heart failure.
What are the side effects of Nebivolol?
Nebivolol may cause a range of adverse reactions, which are grouped by frequency.
Common Side Effects: - Fatigue or tiredness - Headache - Dizziness or light‑headedness - Mild nausea
Serious or Rare Side Effects: - Severe bradycardia or heart block - Marked hypotension - Bronchospasm, especially in patients with asthma or COPD - Allergic reactions such as rash, angioedema, or anaphylaxis
What precautions apply to Nebivolol?
When prescribing Nebivolol, clinicians should consider several safety measures. - Monitor blood pressure: check regularly to avoid excessive lowering. - Assess heart rate: watch for bradycardia, especially in patients with conduction disorders. - Caution in asthma/COPD: β‑blockade may exacerbate bronchospasm. - Avoid abrupt discontinuation: sudden stop can precipitate rebound hypertension. - Store at ambient temperature: keep in the original pack, protect from moisture.
What does Nebivolol interact with?
Nebivolol can interact with other medicines, requiring careful management.
Major Interactions (Avoid): - Non‑selective beta‑blockers: additive bradycardia and AV‑block risk. - Calcium‑channel blockers (verapamil, diltiazem): increased risk of severe bradycardia and heart block. - Other antihypertensives (ACE inhibitors, ARBs, diuretics): may cause excessive hypotension.
Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and renal function. - Antidiabetic agents: beta‑blockade may mask hypoglycaemia symptoms, requiring glucose monitoring.



